Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 1/20 | 0.42 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.42 |
| ▸ | CYP19A1 | P11511 | 4/20 | 0.42 |
| ▸ | ALPG | P10696 | 2/20 | 0.41 |
| ▸ | ALPI | P09923 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | PLAA | Q9Y263 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | CA12 | O43570 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | CA3 | P07451 | 1/20 | 0.39 |
| ▸ | CA4 | P22748 | 1/20 | 0.39 |
| ▸ | CA6 | P23280 | 1/20 | 0.39 |
| ▸ | CA5A | P35218 | 1/20 | 0.39 |
| ▸ | CA7 | P43166 | 1/20 | 0.39 |
| ▸ | CA9 | Q16790 | 1/20 | 0.39 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.39 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.39 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25192326 | 0.84 | CYP19A1 (0.36) | CYP19A1 | |
| SCHEMBL28639324 | 0.80 | PDE4B (0.43) | PDE4BPDE4DCYP19A1ALPGALPI | |
| SCHEMBL30440486 | 0.76 | CYP19A1 (0.49) | CYP19A1 | |
| SCHEMBL30440840 | 0.74 | ALDH1A1 (0.37) | — | |
| SCHEMBL30440993 | 0.74 | PTPN1 (0.41) | — | |
| SCHEMBL11374947 | 0.73 | CYP19A1 (0.46) | PDE4BPDE4DCYP19A1ALPGALPI | |
| SCHEMBL11333173 | 0.73 | CYP19A1 (0.46) | PDE4BPDE4DCYP19A1ALPGALPI | |
| SCHEMBL29973872 | 0.71 | CYP2C9 (0.40) | CA12CA1CA2CA4CA6 | |
| Hydrochloric Acid SCHEMBL10972342 | 0.71 | CYP17A1 (0.47) | CYP19A1ALPGALPITDP1PLAA | |
| SCHEMBL10476950 | 0.70 | ALPG (0.58) | CYP19A1ALPGALPITDP1PLAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115850251-B | 3, 4-methylenedioxyacetophenone imidazole oxime ether derivative, preparation method and application thereof, and medicine for treating Alzheimer's disease | 西北农林科技大学 | 2024-04-12 | — | — | CN | claimed |
| US-11680062-B2 | 3,4-methylenedioxyphenylimidazolylethanonexime ether derivative, preparation method and use thereof, and drug for the treatment of Alzheimer's disease | NORTHWEST A & F UNIVERSITY (CN) | 2023-06-20 | — | — | US | claimed |
| US-20230159503-A1 | 3,4-METHYLENEDIOXYPHENYLIMIDAZOLYLETHANONEXIME ETHER DERIVATIVE, PREPARATION METHOD AND USE THEREOF, AND DRUG FOR THE TREATMENT OF ALZHEIMER'S DISEASE | NORTHWEST A & F UNIVERSITY (CN) | 2023-05-25 | — | — | US | claimed |
| CN-115850251-A | 3,4-methylenedioxyacetophenone imidazole oxime ether derivative, preparation method and application thereof, and medicine for treating Alzheimer's disease | 西北农林科技大学 | 2023-03-28 | — | — | CN | claimed |
| CN-115850251-B | 3, 4-methylenedioxyacetophenone imidazole oxime ether derivative, preparation method and application thereof, and medicine for treating Alzheimer's disease | 西北农林科技大学 | 2024-04-12 | — | — | CN | disclosed |
| US-11680062-B2 | 3,4-methylenedioxyphenylimidazolylethanonexime ether derivative, preparation method and use thereof, and drug for the treatment of Alzheimer's disease | NORTHWEST A & F UNIVERSITY (CN) | 2023-06-20 | — | — | US | disclosed |
| US-20230159503-A1 | 3,4-METHYLENEDIOXYPHENYLIMIDAZOLYLETHANONEXIME ETHER DERIVATIVE, PREPARATION METHOD AND USE THEREOF, AND DRUG FOR THE TREATMENT OF ALZHEIMER'S DISEASE | NORTHWEST A & F UNIVERSITY (CN) | 2023-05-25 | — | — | US | disclosed |
| CN-115850251-A | 3,4-methylenedioxyacetophenone imidazole oxime ether derivative, preparation method and application thereof, and medicine for treating Alzheimer's disease | 西北农林科技大学 | 2023-03-28 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230159503-A1 | 3,4-METHYLENEDIOXYPHENYLIMIDAZOLYLETHANONEXIME ETHER DERIVATIVE, PREPARATION METHOD AND USE THEREOF, AND DRUG FOR THE TREATMENT OF ALZHEIMER'S DISEASE | NOS3, CYP51A1, NOS1 | PDE4B 944/4885PDE4D 1242/4885CYP19A1 71/4885 |
| US-11680062-B2 | 3,4-methylenedioxyphenylimidazolylethanonexime ether derivative, preparation method and use thereof, and drug for the treatment of Alzheimer's disease | NOS3, CYP51A1, NOS1 | PDE4B 944/4885PDE4D 1242/4885CYP19A1 71/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.